This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Putting a Value on Provenge

Disease Prevalence

Now, with many diseases, including most cancers, you can also look at disease prevalence, which is the total number of patients at any one time. Prevalence numbers will be larger than incidence numbers because it takes into account more than one year.

For the purposes of my model, I found finding prevalence figures for prostate cancer difficult, so I chose to use incidence. That's me being conservative, a stance I'll take throughout this model because I'd rather underestimate than overestimate.

Provenge, at least initially, will not be given to all prostate cancer patients. Instead, use will be restricted to patients who have metastatic, androgen-independent (hormone-refractory) disease, which means their cancer has spread beyond the prostate and it is no longer being controlled by hormone treatments. These patients will also be asymptomatic, which means they won't have any outward symptoms, such as bone pain, which could signal new growth of their cancer.

Here comes the hard part -- figuring out the percentage of prostate cancer patients who fit that category, which is labeled "AIPrC" in my model above. After a lot of Googling and research, including looking back at some old analyst notes, my best guess is that 35% of prostate cancer patients are no longer responding to hormone treatments. That's what I used in my revenue model to come up with a total population of AIPrC patients -- the target group for Provenge.

Not all eligible prostate cancer patients will choose to take Provenge. How many will? Frankly, this is an educated guess, especially since Provenge is a first-in-class cancer immunotherapy without precedent.

But again, after some research, I learned that about 65% of hormone-refractory prostate cancer patients choose to move onto chemotherapy treatment for their disease. Provenge, if approved, would slot between hormone therapy and chemotherapy, so for my modeling purposes, I decided to assume that the same 65% of patients would choose Provenge. Given the excellent side-effect profile of Provenge, this percentage might actually end up higher, but again, I like to be conservative.

2 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs